Intellikine: Build-to-Sell in Biotech

Intellikine: Build-to-Sell in Biotech

  • Case
  • Teaching Notes
  • Supplementary Resources
Abstract

The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company’s development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium: The Takeda Oncology Company, Takeda’s business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in ...

You are not authorized to view Teaching Notes. Please contact your librarian for access or sign in to your existing instructor profile.
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles